CVS Group (LSE:CVSG) has more reason than most listed companies to follow the Competition and Markets Authority's work on the UK vet market. The group runs more than 480 veterinary practices across the UK and Australia, and the bulk of its Revenue still comes from British first-opinion and referral clinics, the very businesses the regulator spent more than two and a half years examining.
That review has now reached its end point. The CMA published its final report on 24 March 2026 and its final order on 22 September 2026, with the first measures due to apply to larger practice groups from 23 December 2026. Two days after the order, on 24 September, CVS reported results for the year to 30 June 2026 and said the final remedies order was "in line with our expectations".
The investigation may be over, but it still matters to the Investment case. The rules will shape how CVS prices its services, how it tells clients who owns its practices and how freely it can go back to buying clinics in the UK. Shares fell about 5 per cent on results day as UK growth disappointed.
How CVS Makes Its Money
CVS is mainly a veterinary practice operator. In the year to 30 June 2026, the Veterinary Practices division generated £648.2m of revenue, up 5.2 per cent. The group also has a Laboratories business, whose revenue rose 11.5 per cent to £35.0m, and the online pet pharmacy Animed Direct, which grew 11.1 per cent to £51.0m.
Pet owners pay for consultations, procedures and medicines, and the group also sells subscriptions through its Healthy Pet Club preventive-care scheme. A new version, Healthy Pet Club Advanced, launched in July 2026 and includes unlimited consultations.
CVS has also changed where and how it is listed. It moved from AIM to the Main Market in January 2026 and joined the FTSE 250 in March 2026, according to the results statement.
What the CMA Has Actually Required
The remedies focus on transparency rather than direct price controls on most services. According to the CMA case page, vet businesses will have to show upfront prices for basic services such as consultations and vaccinations, and give written estimates in advance for higher-cost treatment. Practices must publish price lists, and the regulator wants tools that let pet owners compare practices.
The most direct pricing measure concerns prescriptions. In its March 2026 response to the final decision summary, CVS noted that the CMA had raised the proposed prescription fee cap to £21 including VAT for the first drug, with up to £12.50 for each additional drug. CVS called the remedies "workable", while questioning whether all were fully justified.
The company says it has already done much of the work. Price lists have been on practice websites since late 2025, and nearly all UK first-opinion and referral practices now carry joint branding that shows they belong to CVS. Implementation costs of £5.1m were booked as exceptional administrative expenses in the year.
Results Show a Two-Speed Business
Group revenue rose 5.9 per cent to £712.8m and like-for-like sales grew 2.1 per cent, up from 0.2 per cent the year before. Adjusted EBITDA increased 5.1 per cent to £141.5m, with the Margin steady at 19.9 per cent. Adjusted profit before tax rose 7.6 per cent to £84.9m and adjusted Earnings Per Share climbed 6.9 per cent to 85.6p. Statutory profit before tax was £32.0m (£32.6m).
The UK was the weak spot. Like-for-like growth in the veterinary practices division was 1.0 per cent. Management blamed a soft consumer backdrop and extreme heat in the fourth quarter, which led some owners to put off routine appointments. It added that the pandemic-era pet cohort now needs fewer visits.
Australia is growing quickly. Revenue there rose to £79.1m, or 11 per cent of the group total, from £52.1m. CVS made six Australian acquisitions for initial consideration of £43.3m, including the seven-practice Sydney Animal Hospitals, and ended the year with 57 sites. Management said on the results call that the Australian Business generated about £20m of EBITDA before central costs.
Buybacks, Dividends and the Balance Sheet
The board has proposed a final Dividend of 9.0p, up from 8.5p. It is payable on 4 December 2026, and the shares go ex-dividend on 7 November. CVS finished a £20.0m buyback in January 2026 and launched a £50.0m programme in May, of which £11.7m had been spent by the year end.
Net bank borrowings rose to £199.6m from £131.4m, and Leverage rose to 1.63 times from 1.18 times. The £350m bank Facility has been refinanced to May 2030 on improved terms. CVS plans to spend about £50m a year on acquisitions and no more than £30m a year on capital expenditure.
Why the Regulatory Outcome Could Help
Management's main argument is that an end to the investigation should reopen UK dealmaking. The results statement says the remedies are expected to unlock "accretive UK Acquisition opportunities", and CVS has already exchanged contracts on a nine-vet, two-site UK practice for £15.0m of initial consideration.
There are risks. Price lists, written estimates and comparison tools could make pet owners more willing to shop around, which may squeeze fees on routine work. The prescription cap puts a limit on one revenue line. Weak consumer confidence is still weighing on UK volumes. The chief executive is also changing: Richard Fairman said on 30 March 2026 that he plans to retire, and the search for his successor is described as making good progress.
What Comes Next
CVS said the new financial year was "off to a solid start" with positive like-for-like growth, and that it expects to perform in line with market expectations for the year to June 2027. The company-compiled consensus from 11 analysts put average adjusted EBITDA at £150.4m and adjusted EPS at 94.9p. The board is still aiming to return to medium-term like-for-like growth of 4 to 8 per cent.
The next milestones are a retail investor webcast on 1 October, the Annual General Meeting on 25 November and the start of the CMA's first-phase measures on 23 December 2026. A new chief executive appointment is also awaited.
The Bottom Line
CVS has come through the CMA investigation with remedies it describes as expected and workable, and much of the compliance work is already done. Growth in Australia, recurring subscription income and higher adjusted earnings support the business. Against that, the UK is growing slowly, the new transparency rules have not yet been tested on pet owners, Debt is higher and the chief executive is leaving. How the market judges CVS from here will depend on whether UK growth picks up once the new rules are in place.



_11_18_2026_14_37_47_487896.jpg)


Please wait processing your request...